Cipla seeks marketing authorisation of Moderna’s COVID-19 vaccine

HealthCipla seeks marketing authorisation of Moderna’s COVID-19 vaccine

Date:

Cipla seeks marketing authorisation of Moderna’s COVID-19 vaccine

New Delhi: India’s drug regulator may soon grant restricted emergency use authorisation for Moderna’s COVID-19 vaccine, official sources said on Tuesday.

Moderna has also informed that the US Government has agreed to donate a certain number of doses of the Moderna COVID-19 vaccine through COVAX to the Government of India for use and has sought approval from the Central Drugs Standard Control Organisation (CDSCO) for these vaccines.

Mumbai-based pharmaceutical firm Cipla, on behalf of the US pharma major, has requested for import and marketing authorisation of these jabs.

According to the sources, an approval is likely to come anytime as the CDSCO is in favour of doing so.

Read also: This is not a package, it is another hoax: Rahul Gandhi

Cipla filed an application on Monday seeking permission for import of Moderna COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 stating that if the vaccine is approved by the USFDA for EUA, the vaccine can be granted marketing authorization without bridging trial and assessment of safety data of first 100 beneficiaries of vaccines shall be submitted before rolling out in immunization programme.

Share post:

Subscribe

Popular

More like this
Related

How RBI Interest Rate Changes Affect Your Loans, EMIs and Savings

Imagine checking your bank statement and noticing that your...

Government Removes Capital Gains Tax on Foreign Investors in Government Bonds

In a major move to attract foreign investment, the...

India Changes Visa Rules: Foreigners Must Register Before 180-Day Stay Ends

The Central Government has changed immigration rules for foreigners...

What Is Repo Rate? Explained Simply

Whenever the Reserve Bank of India (RBI) announces a...